logo
  

Stock Alert: Lexicon Pharmaceuticals Surges 35%

Shares of Lexicon Pharmaceuticals, Inc. (LXRX) are currently gaining over 35% after the company said it received a regulatory feedback that clears a key hurdle for partnership discussions around sotagliflozin in heart failure.

LXRX is currently trading at $5.33, up $1.41 or 35.97%, on the Nasdaq.

Lexicon Pharmaceuticals said it received U.S. Food and Drug Administration regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Specialty athletic retailer Foot Locker, Inc. reported Friday a second-quarter net profit that plunged from last year, hurt by a sales decline amid markdowns. Quarterly sales met Street estimates. The company also trimmed it adjusted earnings and sales growth guidance for the full-year 2022. Google's hundreds of employees have signed a petition sent to executives demanding extension of abortion care benefits to contract workers. The workers also called to halt donations given to anti-abortion politicians and to expand travel benefits. The petition, circulated by the Alphabet Workers Union, has been signed by over 650 employees at Google's parent company Alphabet Inc. Apple Inc. has released an emergency security update noting that some of its iPhones, iPads and Macs had certain vulnerabilities. The tech major said the flaws potentially allow full admin access to devices. The models affected by the issue include iPhone 6S and later models, several models of the newer iPads, and Mac computers running macOS Monterey and above. The flaws also affect the iPod Touch
Follow RTT